Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS Not Anticipated For Every NME – FDA Official

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER's Sandra Kweder aims to allay industry worries at Drug Industry Association meeting in Boston.

You may also be interested in...



Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword

Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.

Positive Benefit-Risk Is EMEA’s Post-Market Drug Safety Watchword

Speaking at the DIA annual meeting, EMEA officer says agency is implementing a more proactive method for postmarketing risk management.

Post-marketing Study Mandates Could Drive R&D Strategy – DIA Panel

Companies should include post-market “burden” in calculus of drug development decisions, Tufts analyst suggests.

Related Content

Topics

UsernamePublicRestriction

Register

PS067985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel